Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Sickle Cell Disease
Interventions: Voxelotor Only Product in Oral Dose Form, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pirfenidone, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Male Osteoporosis
Interventions: Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3; Drug · Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Androgenetic Alopecia
Interventions: 5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling; Combination Product
Lead sponsor: Levit Dermatology; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Ketorolac, Placebo; Drug · Other
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Tolerance, Healthy Population
Interventions: Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator; Other
Lead sponsor: Mondelēz International, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: HEMOGLOBIN SC DISEASE
Interventions: Mg Pidolate, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Healthy Volunteers
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acute Pain, Pain, Postoperative, Colorectal Surgery
Interventions: Placebo, Ketamine, Acetaminophen, Opioid, Alvimopan; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Neuropathy, Small Fiber
Interventions: Fycompa, Placebo; Drug
Lead sponsor: PNA Center for Neurological Research; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Children, Lacerations, Procedures, Child, Pain
Interventions: hydrocodone/acetaminophen, Sugar water; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 2 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcoholism
Interventions: Ethanol, Placebo, Diphenhydramine, Caffeine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adolescent Idiopathic Scoliosis (AIS)
Interventions: open-label placebo, Treatment as usual; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 10 Years to 18 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prader-Willi Syndrome
Interventions: DCCR, Placebo; Drug
Lead sponsor: Essentialis, Inc.; Industry
Eligibility: 10 Years to 22 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Orange, California

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Obesity
Interventions: Pramlintide+Metreleptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 18
States / cities: Greenbrae, California • La Jolla, California • Denver, Colorado + 15 more

Conditions: COVID-19, Coronavirus, Coronavirus Infection
Interventions: Convalescent Plasma, Saline solution; Biological · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: New Haven, Connecticut • Miami, Florida • New York, New York + 5 more

Conditions: Total Knee Arthroplasty
Interventions: Oxycodone, Placebo Oral Tablet; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cannabis, Psychotic Disorders
Interventions: THC, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab, Placebo, Corticosteroids; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 21 more

Conditions: Infant, Newborn, Diseases, Cardiovascular Insufficiency
Interventions: Hydrocortisone, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 34 Weeks and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Heart Failure
Interventions: AZD3427, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more

Conditions: Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
Interventions: Nintedanib, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Atlanta, Georgia • Baltimore, Maryland • New York, New York + 3 more

Conditions: Ischemic Stroke
Interventions: Privigen, Normal Saline; Biological · Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 45 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Falls Church, Virginia

Search by objective public record fields.

Voxelotor Neurocognitive Function Study

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Novel Combination Therapy for Osteoporosis in Men

Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

ANX-042 Healthy Volunteer Dose Escalation Study

Ketamine in Colorectal Surgery

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair

Chicago Social Drinking Project

Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis

Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

Cannabinoids, Neural Synchrony, and Information Processing

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Hydrocortisone for Term Hypotension

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

IVIG in Acute Ischemic Stroke: A Pilot Study